Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive
bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH)
with tamsulosin hydrochloride for at least 6 weeks